Prepping for Future Demand, SAS Adds JMP Genomic Tools to Its Drug Development Suite | GenomeWeb

As part of a strategy to align with the long-term goals of its pharmaceutical customers, SAS this week said that it has added genomic and proteomic analysis capabilities to its SAS Drug Development software platform, which is primarily targeted to clinical development.

Laurie Rose, director of global health and life science for SAS, said that the integrated system is geared toward researchers who are "breaking down the walls between discovery and development" to bring biomarker and molecular information into their clinical analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.